Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Merck & Co., Inc. is a leading global healthcare company primarily focused on pharmaceuticals and vaccines. Its competitive position is bolstered by a strong portfolio of innovative products, including Keytruda, an immunotherapy drug that has significantly contributed to its revenue in oncology. The company's extensive research and development capabilities, particularly in oncology and infectious diseases, drive its growth.
Merck generates revenue primarily through the sale of prescription medications, vaccines, and animal health products. The company has substantial pricing power due to its strong brand recognition and the critical nature of its products, particularly in oncology and infectious diseases. Its competitive advantages include a robust pipeline of new drugs, a strong sales force, and established relationships with healthcare providers.
Keytruda sales growth, particularly in new indications
Regulatory approvals for new drugs in the pipeline
Market share changes in the oncology segment
Partnerships or collaborations that enhance R&D capabilities
Regulatory changes impacting drug approvals and pricing
Technological disruption in drug development processes
Increased competition from generic drugs and biosimilars
Emerging biotech firms with innovative therapies
High debt levels relative to equity (Debt/Equity of 1.29)
Potential pension obligations impacting liquidity
moderate - Merck's performance is somewhat tied to GDP growth as healthcare spending typically increases during economic expansion, but demand for essential medications remains stable even in downturns.
Interest rates affect Merck primarily through the cost of capital for R&D investments and potential impacts on consumer spending on healthcare. Higher rates could increase financing costs, but the company’s strong cash flow can mitigate this risk.
minimal - Merck has a strong balance sheet and cash flow, reducing reliance on external credit.
growth - due to the potential for significant revenue growth from innovative drug development.
moderate - historical volatility is influenced by drug approval cycles and market competition.
